UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
AMAM holding history
Ambrx Biopharma, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
AMAM overviewAll 13F holders of AMAMFull Q2 2026 holdings
- Shares (Q1 2024)
- 0
- Sold out in Q1 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 6
- Since Q2 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2024 | 0 | $0 | 0.0% | −3,840−100.0% | Sold out | Holders |
| Q4 2023 | 3,840 | $54.7K | <0.1% | −1,734−31.1% | Reduced | Holders |
| Q3 2023 | 5,574 | $64.1K | <0.1% | +5,574 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −56,868−100.0% | Sold out | Holders |
| Q1 2023 | 56,868 | $507.3K | <0.1% | +53,824+1,768.2% | Added | Holders |
| Q4 2022 | 3,044 | $6.91K | <0.1% | −4,923−61.8% | Reduced | Holders |
| Q3 2022 | 7,967 | $9.00K | <0.1% | +7,725+3,192.1% | Added | Holders |
| Q2 2022 | 242 | $1.00K | <0.1% | +242 | New | Holders |